Emerging Technology: Neuropace
Part of Advanced Engineering Principles in Neuromodulation: Next-Generation SCS and DBS Technologies
Details
- Date
- Thursday, January 21, 2027
- Time
- 4:00 PM – 4:15 PM
- Session type
- Pre-Conference Session
- Schedule
- See this day
About
This course provides a deep dive into the advanced engineering behind next-generation spinal cord stimulation (SCS) and deep brain stimulation (DBS) technologies. The morning session spotlights academic leaders sharing foundational concepts critical to innovation in neuromodulation, covering topics such as implantable pulse generator design, electrode technology, novel stimulation paradigms, neural sensing, clinical testing strategies, and the integration of artificial intelligence. During the afternoon, you'll gain insider perspectives from engineers at top companies, as they present cutting-edge technologies recently launched or in active development. This unique structure bridges theory and application, empowering attendees with unparalleled insight into both the scientific fundamentals and real-world breakthroughs propelling neuromodulation forward. Each session features a dedicated faculty Q&A, offering direct engagement with experts. The course is tailored for a broad audience: neural engineers, clinicians, industry professionals, and researchers invested in advancing neuromodulation therapies. Attendees will explore the intricate engineering challenges of modern devices, discover emerging solutions and technologies, and understand how academic and industry innovators are shaping the future of patient care. Focused on the most relevant technological advancements and ongoing innovations, this course delivers practical knowledge that can immediately inform clinical decision-making, inspire new research directions, and support technology development in neuromodulation.
Presenters
-
Brett Wingeier, PhD
Vice-President of Research and Development
NeuroPace · Mountain View, California
Brett Wingeier, PhD, is a biomedical engineer, neuroscientist, and R&D leader with 25+ years of experience in bringing complex, data-driven neurotech to market across multiple indications and platforms. Dr. Wingeier is currently Vice-President of Research and Development at NeuroPace, a publicly-traded neuromodulation company focusing on responsive brain stimulation for treatment of epilepsy. Previously, he served as CEO and co-founder of Magnus Medical, bringing to market the SAINT technology for data-driven, individually-targeted treatment of major depression, and CTO of Halo Neuroscience, where he created Halo Sport, a non-invasive wearable neuromodulation platform for human performance applications. Holding a BSE and Ph.D. in Biomedical Engineering from Tulane University, Dr. Wingeier has published research in biosignals and neural interfaces and is a US registered patent agent with more than 80 issued patents.